Moderna Therapeutics Inc., of Cambridge, Mass., named Stephen Hoge, senior vice president of corporate development and new drug concepts...Relypsa Inc., of Redwood City, Calif., added Paul J. Hastings and David W.J. McGirr to its board

Anne-Marie Swift will serve as vice president and European marketing director...Dendreon Corp., of Seattle, named Lindsay Rocco executive vice president of corporate communications and member of the executive committee

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., named William McClements senior vice president of corporate operations...Xenetic Biosciences plc, of London, added Subash Kapre and Thomas Ulich to its scientific advisory board

Synta Pharmaceuticals Corp., of Lexington, Mass., appointed George Farmer vice president of corporate development

ImmunoGen Inc., of Waltham, Mass., added Kristine Peterson and Dean Mitchell to its board...and added Eunan Maguire senior vice president of strategy and corporate development

ImmunoGen Inc., of Waltham, Mass., added Kristine Peterson and Dean Mitchell to its board...and added Eunan Maguire senior vice president of strategy and corporate development

Medivir AB, of Huddinge, Sweden, appointed Maris Hartmanis president and CEO...NuPathe Inc., of Conshohocken, Pa., appointed Bart J. Dunn vice president of corporate development and licensing

Rib-X Pharmaceuticals Inc., of New Haven, Conn., promoted Erin Duffy to chief scientific officer and Jarrod Longcor to vice president of corporate development

PharmacoFore Inc., of San Carlos, Calif., appointed Joseph Stauffer chief medical officer and vice president of corporate strategy and named Narinder Banait vice president of intellectual property

TetraLogic Pharmaceuticals Inc., of Malvern, Pa., appointed Jonathan B. Lloyd Jones chief financial officer and vice president of corporate development

Patheon, of Toronto, appointed Michael E. Lytton executive vice president of corporate development and strategy and general counsel...PolyTherics Ltd., of London, named John Burt CEO and board member after Keith Powell stepped down

Proteostasis Therapeutics Inc., of Cambridge, Mass., named Alfred Goldberg and Daniel Finley scientific co-founders...It also appointed Suzanne L. Bruhn, Vijay B. Samant and Timothy P. Walbert to its board...Seattle Genetics Inc., of Bothell, Wash., appointed Natasha Hernday vice president of corporate development and promoted Eric Sievers vice president of clinical affairs

The firm also nominated Stuart Strathdee and Ganesh Kishore to its board...Geron Corp., of Menlo Park, Calif., appointed Melanie I. Nallicheri senior vice president of corporate development for the firm's cell therapy programs...Immune Design Corp., of Seattle, named Carlos V. Paya CEO and board member

Stellar Biotechnologies Inc., of Port Hueneme, Calif., appointed Michael R. McClurg vice president of business development and marketing and changed Darrell Brookstein's title to executive vice president of corporate development and finance

Addex Pharmaceuticals Ltd., of Geneva, proposed adding Hoyoung Huh and Oleg Nodelman to the board...Codexis Inc., of Redwood City, Calif., named Jacques Beaudry-Losique vice president of corporate development and strategy

The firm also named Lori M. Henderson vice president, general counsel and secretary...Anadys Pharmaceuticals Inc., of San Diego, named Kevin L. Eastwood senior vice president of corporate development, promoted James Appleman to senior vice president of research and chief scientific officer, appointed James L. Freddo to the board and named Stelios Papadopoulos chairman

Oncothyreon Inc., of Seattle, appointed Julie M. Eastland chief financial officer and vice president of corporate development

BioMarin Pharmaceutical Inc., of Novato, Calif., appointed William D. Young and Kenneth M. Bate to its board...Ensemble Therapeutics Corp., of Cambridge, Mass., named Ted Hibben senior vice president of corporate development

Rigel Pharmaceuticals Inc., of South San Francisco, promoted Raul R. Rodriguez to president, Dolly Vance to general counsel and executive vice president of corporate affairs and Ryan Maynard to executive vice president and chief financial officer